Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

• Status: Completed
• Trial end date: 2018-10-10
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
• Treatments: Antihypertensive Agents; Arotinolol

Criteria

Inclusion Criteria:

• Aged between 18-75 years-old;

• Chronic kidney disease stage 5 with haemodialysis treatment for 2 months;

• Patients with blood pressure≥140/90 mmHg after receiving 2 or 3 antihypertensive medications for 2 weeks;

• Patients who receiving alfa or beta blockers will be washed out for 2 weeks;

• Written informed consent

Exclusion Criteria:

• Unstable angina, myocardial infarction, symptomatic or continuous arrhythmia, cardiosurgery in the last 2 months;

• Patients who taking class I antiarrhythmic drugs;

• Resting heart rate less than 60;

• Patients with systolic pressure less than 90 mmHg;

• Patients with chronic obstructive pulmonary disease and asthma;

• Patients with cerebral infarction in the last 2 weeks;

• Severe disorders of liver function;

• Allergy to the arotinolol;

• Patients who planning to have kidney transplantation in the near future;

• Pregnancy and breast-feeding;

• Malignant tumor